Tetraspanin cd81 is an adverse prognostic ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Tetraspanin cd81 is an adverse prognostic marker in acute myeloid leukemia
Auteur(s) :
Boyer, Thomas [Auteur]
Guihard, Soizic [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Roumier, Christophe [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Peyrouze, Pauline [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Gonzales, Fanny [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Berthon, Celine [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Quesnel, Bruno [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Preudhomme, Claude [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Behal, Helene [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Roche-Lestienne, Catherine [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Cheok, Meyling [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Guihard, Soizic [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Roumier, Christophe [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Peyrouze, Pauline [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Gonzales, Fanny [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Berthon, Celine [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Quesnel, Bruno [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Preudhomme, Claude [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Behal, Helene [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Roche-Lestienne, Catherine [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Cheok, Meyling [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Titre de la revue :
Oncotarget
Nom court de la revue :
Oncotarget
Numéro :
7
Pagination :
62377-62385
Date de publication :
2016-09-20
ISSN :
1949-2553
Mot(s)-clé(s) en anglais :
prognosis
flow cytometry
tetraspanin
CD81
acute myeloid leukemia
Mesh:Adult
Mesh:Aged
Mesh:Biomarkers
Mesh:Tumor/metabolism*
Mesh:Cell Membrane/metabolism
Mesh:Disease-Free Survival
Mesh:Female
Mesh:Flow Cytometry
Mesh:Follow-Up Studies
Mesh:Granulocyte Precursor Cells/metabolism
Mesh:Granulocyte Precursor Cells/ultrastructure
Mesh:Humans
Mesh:Kaplan-Meier Estimate
Mesh:Leukemia
Mesh:Myeloid
Mesh:Acute/blood
Mesh:Leukemia
Mesh:Myeloid
Mesh:Acute/genetics
Mesh:Leukemia
Mesh:Myeloid
Mesh:Acute/mortality*
Mesh:Leukemia
Mesh:Myeloid
Mesh:Acute/pathology*
Mesh:Leukocyte Count
Mesh:Male
Mesh:Middle Aged
Mesh:Mutation
Mesh:Nuclear Proteins/genetics
Mesh:Prognosis
Mesh:Tetraspanin 28/metabolism*
Mesh:Young Adult
Mesh:Age Factors
flow cytometry
tetraspanin
CD81
acute myeloid leukemia
Mesh:Adult
Mesh:Aged
Mesh:Biomarkers
Mesh:Tumor/metabolism*
Mesh:Cell Membrane/metabolism
Mesh:Disease-Free Survival
Mesh:Female
Mesh:Flow Cytometry
Mesh:Follow-Up Studies
Mesh:Granulocyte Precursor Cells/metabolism
Mesh:Granulocyte Precursor Cells/ultrastructure
Mesh:Humans
Mesh:Kaplan-Meier Estimate
Mesh:Leukemia
Mesh:Myeloid
Mesh:Acute/blood
Mesh:Leukemia
Mesh:Myeloid
Mesh:Acute/genetics
Mesh:Leukemia
Mesh:Myeloid
Mesh:Acute/mortality*
Mesh:Leukemia
Mesh:Myeloid
Mesh:Acute/pathology*
Mesh:Leukocyte Count
Mesh:Male
Mesh:Middle Aged
Mesh:Mutation
Mesh:Nuclear Proteins/genetics
Mesh:Prognosis
Mesh:Tetraspanin 28/metabolism*
Mesh:Young Adult
Mesh:Age Factors
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
CD81 is a cell surface protein which belongs to the tetraspanin family. While in multiple myeloma its expression on plasma cells is associated with worse prognosis, this has not yet been explored in acute myeloid leukemia ...
Lire la suite >CD81 is a cell surface protein which belongs to the tetraspanin family. While in multiple myeloma its expression on plasma cells is associated with worse prognosis, this has not yet been explored in acute myeloid leukemia (AML). We measured membrane expression of CD81 on AML cells at diagnosis, evaluated its association with AML characteristics and its influence on patient outcome after intensive chemotherapy in a cohort of 134 patients. CD81 was detected in 92/134 (69%) patients. Patients with AML expressing CD81 had elevated leukocyte count (P=0.02) and were more likely classified as intermediate or adverse-risk by cytogenetics (P<0.001). CD81 expression had a negative impact on survival (event-free survival, overall survival and relapse-free survival) in univariate (P<0.001) and in multivariate analyses (P=0.003, 0.002 and <0.001, respectively). CD81 has a negative impact on OS in patients with NPM1 mutation (P=0.01) and in patients ELN-favorable (P=0.002). In conclusion, this cell surface marker may be a new prognostic marker for diagnostic risk classification and a potential therapeutic target for drug development in AML.Lire moins >
Lire la suite >CD81 is a cell surface protein which belongs to the tetraspanin family. While in multiple myeloma its expression on plasma cells is associated with worse prognosis, this has not yet been explored in acute myeloid leukemia (AML). We measured membrane expression of CD81 on AML cells at diagnosis, evaluated its association with AML characteristics and its influence on patient outcome after intensive chemotherapy in a cohort of 134 patients. CD81 was detected in 92/134 (69%) patients. Patients with AML expressing CD81 had elevated leukocyte count (P=0.02) and were more likely classified as intermediate or adverse-risk by cytogenetics (P<0.001). CD81 expression had a negative impact on survival (event-free survival, overall survival and relapse-free survival) in univariate (P<0.001) and in multivariate analyses (P=0.003, 0.002 and <0.001, respectively). CD81 has a negative impact on OS in patients with NPM1 mutation (P=0.01) and in patients ELN-favorable (P=0.002). In conclusion, this cell surface marker may be a new prognostic marker for diagnostic risk classification and a potential therapeutic target for drug development in AML.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Collections :
Date de dépôt :
2019-12-09T18:15:29Z
2020-04-09T08:56:47Z
2020-04-09T08:56:47Z
Fichiers
- 11481-176373-3-PB.pdf
- Version éditeur
- Accès libre
- Accéder au document